Counterfeit Ozempic Indictment in Tampa: Federal Smuggling and Counterfeit Drug Exposure for Florida Distributors and Med Spas

Two men are charged in the Middle District of Florida with buying counterfeit Ozempic from unauthorized sources in China and selling it to U.S. drug distributors at a discount. The Justice Department release describes fake packaging, inserts, pen labels and needles built to look authentic, and it says the scheme ran from July 2023 to April 2024, continuing after FDA seized counterfeit Ozempic and issued a public warning in December 2023.

These are allegations, and both defendants are presumed innocent. For a distributor, pharmacy buyer or med spa owner who bought discounted semaglutide in that period, the indictment is a map of the evidence the government treats as important: where the product came from, what it cost, and what the buyer had been told.

The government's case runs on the paper: where the pens came from, what they cost, and what the buyer had been told.

Key Takeaways

• A Tampa indictment charges conspiracy, three smuggling counts under 18 U.S.C. § 545, and two counterfeit-drug counts tied to 21 U.S.C. § 331(i)(3).
• Knowing counterfeit-drug violations carry up to 10 years under 21 U.S.C. § 333(b)(8), and each smuggling count carries up to 20 years.
• FDA's Office of Criminal Investigations and the Middle District of Florida brought the case, which puts Florida distributors, pharmacies and med spas inside that reach.
• A deep discount and a public FDA warning are the facts prosecutors use to argue that a buyer knew the product was suspect.
• Counsel in place before agents call decides whether a purchaser is treated as a witness, a subject or a target.

What Happened: The Tampa Counterfeit Ozempic Indictment

On September 29, 2026, the U.S. Attorney's Office for the Middle District of Florida announced charges against two Indian nationals. One count alleges conspiracy to commit smuggling and to defraud the United States. Three counts allege smuggling. Two counts allege selling counterfeit drugs and holding them for sale. The release states a maximum penalty of 71 years in prison for each defendant.

One defendant was extradited from Italy after an INTERPOL Red Notice and made his initial appearance in Tampa the same day. The Justice Department's Office of International Affairs handled the extradition. The investigation was run by the FDA Office of Criminal Investigations, with the Criminal Division's Health and Safety Unit assisting the prosecution. The charging document is an accusation. It is not proof, and nothing in the release says any downstream buyer is under investigation.

What the Government Is Building

Read the release for its facts rather than its adjectives. The product allegedly came from unauthorized sources abroad. It was sold to distributors at significantly lower cost than genuine Ozempic. It allegedly continued to move after FDA publicly seized counterfeit Ozempic and warned the market. Each of those facts does work in a case: source goes to smuggling, discount goes to knowledge, and the post-warning period goes to willfulness.

Agents pull purchase orders, wire records, invoices, lot numbers and shipping labels. A buyer does not need to have touched the importation to end up in that paper trail.

In supply-chain cases, agents work the paper. They pull purchase orders, wire records, invoices, lot numbers, shipping labels and the messages between buyer and seller. A buyer does not need to have touched the importation to end up in that paper trail. That is why a federal investigation of a counterfeit-drug importer so often produces grand jury subpoenas to the companies that bought from it. Receiving one does not mean you are charged. It does mean someone in the government is asking what you knew, and when.

Exposure and Charges for Distributors, Pharmacies and Med Spas

Four statutes frame the exposure. Conspiracy under 18 U.S.C. § 371 carries up to five years and requires an agreement plus an act in furtherance. Smuggling under 18 U.S.C. § 545 requires that the person knowingly and willfully, with intent to defraud the United States, brought merchandise into the country clandestinely or without proper invoicing, and it carries up to 20 years.

The drug counts sit in the Food, Drug, and Cosmetic Act. Section 331(i)(3) prohibits any act that causes a drug to be a counterfeit drug, and the sale, dispensing or holding for sale of a counterfeit drug. A counterfeit drug, as 21 U.S.C. § 321(g)(2) defines it, is one sold under another manufacturer's mark or likeness without authorization. Under 21 U.S.C. § 333(b)(8), a knowing violation carries up to 10 years. The word that matters is knowing. For a buyer or reseller, the whole case is usually about knowledge.

The Supply-Chain Statute and the Florida Routes

The federal supply-chain statute adds a second layer. Trading partners in the drug distribution chain have duties to deal only with authorized partners and to quarantine and investigate suspect product, set out beginning at 21 U.S.C. § 360eee-1. A purchaser who skipped those steps is not automatically a criminal defendant, but the missed verification becomes a fact the government will use to argue deliberate ignorance. Sentencing exposure then turns on the Guidelines range for the offense conduct, the volume of product, and any enhancement tied to risk to patients.

Product enters through the ports and air cargo hubs in the Southern District of Florida and moves to buyers across the state.

In South Florida, the practical routes are familiar. Product enters through the ports and air cargo hubs in the Southern District of Florida and moves to buyers across the state, which is why Middle District and Southern District prosecutors both see these cases. A med spa that bought a few cases of discounted pens and a wholesaler that moved thousands are in very different positions, but both can receive the same subpoena.

Critical Mistakes People Make Early

The first mistake is talking to FDA OCI agents without counsel. Agents often describe a visit as routine and say you are only a witness. They do not decide your status, and nothing said at a front desk is off the record. The second is continuing to sell remaining inventory because it has not been tested. If product is suspect, selling it after you have notice creates the knowledge evidence the government lacks today.

The third is destroying, returning or relabeling product, or cleaning up purchase records, once an inquiry begins. That conduct can be charged on its own under 18 U.S.C. § 1519, and obstruction cases are often easier to prove than the underlying drug counts. The fourth is calling the supplier to compare stories. The fifth is assuming that a licensed distributor's invoice settles the question. It does not, if the surrounding facts should have raised one.

Strategic Defense Approach

The work starts with controlling the facts before anyone else characterizes them. Quarantine remaining product under counsel's direction and document lot numbers. Preserve every purchase record, message and payment. Authenticate the product through the manufacturer's verification process so the question of what you held has a documented answer. Do all of it through a privileged review, not an internal email chain.

"Source goes to smuggling, discount goes to knowledge, and the post-warning period goes to willfulness."— Aaron M. Cohen, Principal Attorney

Then establish where you stand. A federal target letter attorney or a federal grand jury subpoena attorney can often learn from the assigned prosecutor whether a client is viewed as a witness, a subject or a target, and that answer shapes everything that follows. If the facts support it, a pre-charge presentation can show that the buyer had real verification practices and no reason to doubt the source. If the facts are worse, the decision becomes whether to cooperate, and a proffer session or queen for a day agreement should never be signed without a clear-eyed view of the evidence the government already holds. Cooperation has value early and loses it quickly.

Why Timing Matters

Counterfeit-drug and smuggling cases move from the importer outward. The first defendants are charged, and the government then decides who else to charge, who to treat as a witness and who to leave alone. That decision is fluid while agents are still reading the paper. Buyers who engage counsel, preserve records and present their verification history during that window are in a different position from those who respond only after an indictment.

The charges are also recent, the extradition just occurred, and the government has said publicly that it intends to pursue pharmaceutical supply-chain cases. If you bought discounted semaglutide in 2023 or 2024 and have not reviewed that file with a lawyer, the time to do it is before a subpoena arrives.

Common Questions

Under Federal Investigation Over Drug Purchasing or Supply-Chain Records in Florida?

If you bought semaglutide or other injectable products through a distributor and have heard from FDA, a federal agent or a grand jury, the first conversation should be with counsel. As a white collar defense attorney and federal criminal defense attorney, Aaron M. Cohen handles federal investigation defense, FDA investigations and pre-indictment matters for distributors, pharmacies and med spas in the Middle and Southern Districts of Florida and nationwide. Contact the firm for a confidential consultation at 561.542.5494. Every case is different, and nothing here guarantees an outcome.

AMC Defense Law represents distributors, pharmacies and med spas in FDA and federal investigations in Florida and nationwide.

If you or your loved ones have been arrested or contacted by federal agents, call Aaron M. Cohen, 24 hours a day to get help.

This article is for general information only and is not legal advice. Reading it does not create an attorney-client relationship. The charges described are allegations, and every defendant is presumed innocent. Prior results do not guarantee a similar outcome. Consult a licensed attorney about your specific situation.